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Von Hippel Lindau (VHL) disease (OMIM 193300) is a 
hereditary cancer predisposition syndrome. The pattern of 
inheritance is autosomal dominant, characterized by high 
penetrance [1]. In most cases, the patient inherits a germline 
mutation from one parent, and a second “hit” can be detected 
in the tumor tissue [2,3]. Nonetheless, 20% of VHL diseases 
are reported as sporadic, due to a de novo mutation [4]. The 
mutation occurs in the VHL gene (OMIM 608537), located on 
chromosome 3p25–26, which encodes for a tumor suppres-
sion protein [5]. The mutations of the VHL gene, as well as 
the disease phenotypes, are highly varied, and the syndrome 
predisposes to the development of multiple organ malig-
nant and benign tumors [2]. The most frequent are retinal 
or central nervous system (CNS) hemangioblastomas, renal 
clear cell carcinoma, and pheochromocytoma [6].
The VHL syndrome incidence rate is 1:36,000 live 
births [6]. In particular, a retinal capillary hemangioblastoma 
(RCH) prevalence is described in approximately half of 
patients with VHL syndrome [7,8]. RCHs represent one of 
the earliest manifestations of the syndrome, with a mean 
age onset of 26 years [1,9]. They are detected during fundus 
oculi examination as orange-red vascular hamartomas, fed 
by tortuous and dilated feeder and drainage vessels. RCHs 
are described as multiple in one-third of cases and bilateral 
in half of affected patients [10]. The peripheral retina is more 
frequently affected, with only 11%–15% of RCHs arising 
juxtapapillary [10]. RCHs might remain quiescent or grow 
progressively, leading to visual impairment and exudative or 
tractional secondary effects [11]. Fluorescein angiography 
(FA) adds information by highlighting the tumors and their 
associated abnormal vascular supply [12]. Whenever possible, 
treatment consists of laser photocoagulation of the lesion [13]. 
However, in literature alternative treatment techniques are 
described, such as cryotherapy, photodynamic therapy (PDT), 
thermotherapy, intravitreal injections of anti-VEGF, and 
vitreoretinal surgery [8]. The aim of this study is to describe 
genetic analysis, treatment results, and complications of 
patients affected by RCH in VHL syndrome.
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Purpose: To describe genetic analysis, treatment results, and complications of patients affected by retinal capillary 
hemangioblastoma (RCH) in von Hippel Lindau (VHL) syndrome.
Methods: We collected 17 patients with VHL syndrome, who underwent a molecular test and an ophthalmic evalua-
tion at the Eye Clinic of the University Hospital of Florence from January 2005 to February 2020. We focused on eyes 
showing RCHs examined using color fundus photographs, fluorescein angiography, and optical coherence tomography.
Results: Eight eyes of six patients (6/17; 35%) showed RCHs at the fundoscopic examination. All RCHs were treated with 
laser therapy. Three eyes underwent episcleral surgery, one eye showing vitreous hemorrhage received three intravitreal 
(IV) anti-VEGF injections and three cryotherapy procedures, and one eye underwent vitrectomy. In patients with RCHs, 
five were characterized by a truncating mutation of the VHL protein, and one patient showed a missense mutation. We 
have reported two VHL mutations not reported in literature.
Conclusions: Patients with multiple RCHs, who developed RCH secondary effects, showed truncating mutations of the 
VHL protein. We recommend early screening and close monitoring, especially if RCHs are detected at presentation, 
for every patient with VHL syndrome independently of the results of the molecular test for a missense or a truncating 
mutation in VHL.
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METHODS
We retrospectively studied 17 patients affected by VHL 
syndrome (9 patients were females; 52,9%) who had been 
examined (with a molecular test and an ophthalmic evalu-
ation) at the Careggi Teaching Hospital from January 2005 
to February 2020; more specifically, we considered patients 
affected with RCHs (6 patients, 6/17; mean age 39±14 
years). This study was approved by the local research Ethics 
Committee (Careggi Teaching Hospital Ethics Committee) in 
accordance with the principles of the Declaration of Helsinki. 
Informed written consent was obtained from all individual 
participants included in the study.
Sanger sequencing and MLPA for mutation screening: Whole 
blood is taken from the patient's venous circulation and stored 
at 4 °C. Subsequently 200 µl of whole blood are used for 
genomic DNA extraction using the QIAsymphony CDN Kit, 
QIAsynphony SP (Qiagen, Hilden, Germany), which allows 
to obtain the eluted DNA ready for use. In short, the extrac-
tion procedure is divided into various steps starting with a 
lysis, where lysate and magnetic particles are transferred in 
the sample preparation cartridge, subsequently DNA binds 
to magnetic particles, and then two separation steps follow 
magnetic interspersed with a wash to arrive at the release of 
the eluate. The DNA quality and quantity were measured with 
a Qubit ds assay on Qubit 2.0 Fluorometer (Thermo Fisher 
Scientific, Monza, Italy). When we searched for germline 
mutations of the VHL gene, the coding regions and exon-
intron boundaries were amplified by PCR: 100 ng of DNA 
was PCR-amplified using the forward and revers primers 
located at exon-intron boundaries, performed in standard 
reaction conditions with an initial denaturation at 95 °C for 
5 min followed by 30 cycles each composed of 1 min at 95 
°C, 30 s at 58 °C, 30 s at 72 °C, and a final extension of 7 
min at 72 °C. Total PCR products were than purified using a 
PCR purification kit (Qiagen, Milan, Italy). To perform the 
cycle-sequencing reaction, 5 ng of DNA were then blended 
with each primer (0.8 µM) in a terminator ready reaction 
mix containing big dye terminators (Applied Biosystems, 
Thermo Fisher Scientific) and submitted to 1 minute at 96 
°C and 25 cycles at 96 °C for 10 s, 50 °C for 5 s, 60 °C for 4 
min. A second purification step was necessary for the big dye 
removal with DyeEx 2.0 Spin Kit (Qiagen). Five µl of marked 
and purified DNA were submitted to sequencing analysis 
with ABI PRISM 310 Genetic Analyser (Applied Biosystems). 
Subsequently we searched eventual genomic rearrange-
ments using the MLPA test (multiplex ligation-dependent 
probe amplification/MRC Holland, SALSA Kit P016-C2 
VHL version C2) approach. For analysis of MLPA data we 
used Coffalyser.Net software (MRC, Holland, Netherlands). 
Analysis of variant by querying different databases i.e. 
Clinvar-NCBI-NIH and Intervar (Clinical Interpretation of 
genetic variants by ACMG/AMP 2015 guideline) allowed us 
to classify the variant [14].
Treatment and ophthalmic assessment of RCHs: The standard 
follow-up ophthalmologic examination included measure-
ment of best corrected visual acuity (BCVA),, tonometry, and 
funduscopic evaluation. In addition, all patients underwent, 
before or after the treatment or both, fundus photography 
(Zeiss Retinograph Carl Zeiss, Dublin, CA), ultrawide field 
scanning laser ophthalmoscopy (UWF-SLO; Daytona, Optos, 
Dunfermline, UK), optical coherence tomography (OCT) 
scanning (Topcon 3D OCT-1000, Topcon Medical Systems 
Inc., Oakland, NJ, and Heidelberg Spectralis SD-OCT, 
Heidelberg Engineering, Dossenheim, Germany), and FA 
(Heidelberg Retina Angiograph 2 Heidelberg Engineering; 
Zeiss Retinograph Carl Zeiss). Argon green laser was 
performed using a QuadrAspheric Indirect Contact Laser 
Lens (Volk, Mentor, OH) in one or more sessions. The 
photocoagulation was targeted on the retina adjacent to 
the tumor, and then the laser was directed on the top of the 
hemangioblastoma, as suggested by Schmidt et al., to reduce 
the risk of retinal detachment [13]. Feeder vessels were not 
treated directly using laser to avoid vitreous hemorrhage. 
Additional individualized therapies were collected and have 
been described.
RESULTS
We included 17 patients carrying mutations in VHL from 
ten families. Specifically, six patients (6/17; 35.3%), from six 
different families (Figure 1), were characterized with RCHs 
at the funduscopic examination. The clinical findings of the 
patients with VHL syndrome are reported in Table 1.
Genetic analysis: The results of the genetic analysis revealed 
four missense mutations, four nonsense mutations, one frame-
shift mutation, and one genomic deletion. Genetic results are 
summarized in Table 2. Nonsense mutations were reported 
in three out of six patients (3/6; 50%) affected by RCHs: In 
detail, the premature translational stop signal was at the 
codon 161 (c.481C> T; p.Arg161Ter) in patient P5, and patients 
P8 and P9 were characterized by the same mutation in VHL 
(c.337C> T; p.Arg113Ter) although the patients were not in 
the same family (family 4 and family 5, respectively). Patient 
P10 reported a genomic deletion (c.341+1_341–1(463*1_?)) 
and patient P2 a missense mutation (novel mutation, not 
reported in literature), causing a replacement of a proline 
with a leucine at nucleotide 192 (c.575C> T; p.Pro192Leu). 
Finally, a novel frameshift mutation was reported in patient 
P1, due to a deletion of a cytosine in position 154 (c.461delC; 
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p.Pro154Glnfs4*) which causes sliding of the reading frame. 
We examined both parents of five out of six patients affected 
by RCHs and identified three de novo mutations in patients 
P1, P8, and P10.
Management and follow-up of RCHs: Eight eyes, of six 
patients with VHL syndrome (6/17; 35%), showed RCHs at 
the first fundoscopic examination. Mean age at diagnosis of 
the ocular disease was 30 years (range 14–42 years). Mean 
BCVA at the first ophthalmic visit was 20/32 (range 20/640 
to 20/20). All observed RCHs were peripheral and did not 
involve the posterior pole. At presentation, only two eyes of 
two different patients (2/6; 33%; patients P1 and P2) showed 
a single RCH; the remaining six eyes of four patients (4/6; 
66.7%; patients P5, P8, P9, and P10) showed multiple tumors 
with bilateral involvement in two patients (patients P5 and 
P8). At diagnosis, secondary tractional or exudative effects 
or both of RCHs had caused retinal detachment in two eyes 
(patient P5 and P10) and severe retinal exudation in one eye 
(patient P8). All patients underwent laser photocoagulation 
of the RCHs. Additional treatment techniques were neces-
sary in four eyes: cryotherapy (patients P8, P5, P10, and 
P9) and intravitreal (IV) injections of anti-VEGF (three IV 
injections were performed in the left eye of patient P8). A 
scleral buckle was performed in three eyes (patients P9, P5, 
and P10). Follow-up lasted an average of 99 months (range 
6–168 months). During follow-up, patient P2 underwent 
barrage laser and pars plana vitrectomy for the development 
of a retinal tear and a full-thickness macular hole (FTMH), 
respectively; patient P8 developed a vitreous hemorrhage, 
and patients P5 and P9 a chronic retinal detachment with 
neovascular glaucoma (NVG). All these events happened in 
the affected eyes. At the end of the follow-up period, the mean 
BCVA was 20/32 (range no light perception (nlp) to 20/20)). 
Regarding the 11 patients with VHL syndrome who did not 
show RCHs at the first fundoscopic examination, we did not 
observe any further retinal findings during the follow-up 
period (mean follow-up of 74 months; range 6–1480).
Figure 1. Pedigrees of the six patients with VHL syndrome characterized by RCHs.
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Descriptions of RCH clinical cases:
Patient P1—A 24-year-old woman underwent her 
first retinal examination due to the detection of a cerebellar 
hemangioblastoma. BCVA was 20/20 in both eyes (OU); 
at the fundus examination, the right eye (OD) showed no 
alterations, while a single peripheral RCH (inferior nasal) was 
present in the left eye (OS; Figure 2). Laser was performed on 
the retina surrounding the lesion in one session. During the 
follow-up (the last performed in September 2019), the tumor 
in OS was stable in size without exudation, and we did not 
detect the development of RCHs in OD.
Patient P2—A 42-year-old woman was referred to the 
Eye Clinic due to a lesion in OS. OD was normal. BCVA 
was 20/25, and a peripheral RCH with a macular pseudohole 
was observed at the fundoscopic examination (Figure 3). The 
tumor was treated using laser photocoagulation and required 
several treatment sessions. One week after the first laser 
session, the pseudohole progressed to a lamellar macular hole 
(LMH) and after some months, to a FTMH. BCVA worsened 
to 20/63 in 2012, and pars plana vitrectomy was successfully 
performed: The macular epiretinal membrane and internal 
limiting membrane were peeled. During follow-up, a retinal 
tear was detected (in 2014), and it was treated using a barrage 
laser. The last follow-up visit (in September 2019) revealed 
a good macular profile and RCH regression; BCVA in OS 
was 20/25. During the follow-up, OS did not develop lesions.
Patient P5—A 32-year-old man accessed the ophthalmic 
emergency service in 2010. BCVA was 20/32 in OD, and the 
fundoscopic examination revealed three peripheral RCHs 
with retinal detachment and a juxtapapillary fibrovascular 
membrane (Figure 4). Moreover, two small retinal lesions 
were detected in OS, and BCVA of OS was 20/20. The patient 
underwent retinal surgery in OS (scleral buckle and transs-
cleral cryotherapy); then, the lesions of both eyes were treated 
with multiple laser sessions. The CNS imaging revealed the 
presence of multiple cerebellar and spinal hemangioblas-
tomas. In 2012, cataract surgery was performed in OD. In 
August 2019, BCVA was 20/20 OU, and regression of all the 
RCHs was observed.
Patient P8—In October 2019, visual impairment 
was diagnosed in a 14-year-old boy. BCVA was 20/20 and 
20/640 in OD and OS, respectively. Four peripheral RCHs 
were detected in OD. In OS, multiple RCHs were present; 
the largest was located temporally, and it consisted in the 
coalescence of many RCHs. The visual impairment of OS 
was due to the severe exudative process which involved the 
macula. Moreover, FA revealed numerous microhemangio-
blastomas that could not be detected using other diagnostic 
techniques. Laser therapy was performed in OU, but vitreous 
hemorrhage occurred in OS. Therefore, three anti-VEGF IV 
(bevacizumab) and simultaneous transscleral cryothera-
pies were performed under general anesthesia. Many laser 
sessions were necessary to obtain regression of the RCHs. 
Further investigations revealed the presence of a cerebellar 
hemangioblastoma.
Patient P9—In 2005, a 32-year-old woman was exam-
ined at the clinic. The patient had been diagnosed in 2000 with 
multiple cerebellar and spinal hemangioblastomas. BCVA 
was 20/20 and 20/25 in OD and OS, respectively. No retinal 
abnormalities were found in OD. A peripheral superior RCH, 
already partially treated with laser photocoagulation, was 
observed in OS. FA showed the presence of many tiny RCHs 
that surrounded the major lesion. Further laser treatments 
were scheduled, but the patient was lost at follow-up. She 
Table 2. Genetic results.
Family 






F1 c.461delC 2 p.Pro154Glnfs4* Frameshift Uncertain significance Novel
F2 c575C>T 3 p.Pro192Leu Missense Uncertain significance Novel
F3 c.481C>T 3 p.Arg161Ter Nonsense Pathogenic Yes
F4 c.337C>T 1 p.Arg113Ter Nonsense Pathogenic Yes
F5 c.337C>T 1 p.Arg113Ter Nonsense Pathogenic Yes
F6 c.341+1_341–1(463*1_?) 1–3 c.341+1_341–1(463*1_?) Genomic deletion Pathogenic Yes
F7 c.355T>C 1 p.Phe119Leu Missense Pathogenic Yes
F8 c.154G>T 1 p.Glu52Ter Nonsense Uncertain significance Yes
F9 c.194C>G 1 p.Ser65Trp Missense Pathogenic Yes
F10 c.524A>G 3 p.Tyr175Cys Missense Pathogenic Yes
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came to the ophthalmic emergency service three years later; 
BCVA of OS had decreased to 20/640, and she presented an 
exudative retinal detachment that involved the posterior pole. 
The partially treated RCH of OS had become more extensive, 
and FA revealed that the tiny RCHs had increased in number. 
In 2008, a scleral buckle with transscleral cryotherapy was 
performed in OS; however, at follow-up the retinal detach-
ment was still present, and the patient developed neovascular 
glaucoma with a seclusio pupillae. Visual acuity of OS was 
no light perception. RCHs were not detected during follow-up 
in OD.
Patient P10—In 2009, a 37-year-old man accessed 
the emergency service, and a nasal retinal detachment was 
detected in OD. Multiple RCHs were present in all the quad-
rants; the biggest lesion was located nasally. It was made up 
of the coalescence of many tumors and measured approxi-
mately 4 optic disc diameters (DD). BCVA was 20/400, also 
due to the presence of macular scars. CNS imaging detected 
multiple cerebellar and bulbar hemangioblastomas. Nasal 
scleral buckle and cryotherapy were performed, and several 
laser photocoagulation treatment sessions were performed. In 
2012, the patient developed a new tractional retinal detach-
ment in OD and NVG. Visual acuity of OD was nlp. At the 
last follow-up visit (in 2019), we did not detect RCHs in OS. 
Clinical details are summarized in Table 1.
DISCUSSION
We report different treatment techniques, long-term follow-
up, and molecular tests of six patients with VHL syndrome 
who presented RCHs in eight eyes. The management and 
treatment of RCHs in VHL syndrome are not standardized. 
It is well-known that laser photocoagulation is the gold 
standard in the case of peripheral tumors smaller than 1 DD 
[8,13,15]. However, different approaches may be required 
Figure 2. Patient P1. Color fundus photograph (A) shows the single peripheral RCH after one session of laser photocoagulation treatment 
(2015). Fluorescein angiography (FA; B) displays the feeder vessels and the early hyperfluorescence of the retinal capillary hemangioblastoma 
(RCH) lesion (2015). The ultrawide field (UWF) color fundus photograph (C) shows the inferonasal location of the RCH (2019). During 
follow-up, the lesion remained stable. UWF autofluorescence imaging (D) shows the retinal scar following the treatment (hypoautofluores-
cence lesion).
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Figure 3. Patient P2. FA of the right eye of patient P2 shows the RCH (hyperfluorescence round lesion) before (B) and after (D) multiple 
laser sessions. The color fundus photograph shows the retinal capillary hemangioblastoma (RCH) after the first laser session (C). The optical 
coherence tomography (OCT) scan shows the irregularities of the inner retinal surface before treatment (pseudohole; 2009; A). Two months 
after the beginning of the laser treatment, the OCT scan shows a lamellar macular hole (E) and then a full-thickness macular hole (FTMH) 
in 2010 (F). In particular, hyperreflective abnormalities above the RPE can be seen in the bed of the hole (F) which appear as round yellowish 
lesions in the color fundus photograph (G). The yellow lesions are particularly evident in the magnified foveal image performed in 2012 
which shows the increase in the number and size of the yellowish dots during follow-up (G). The OCT scan (H) shows the closure of the 
FTMH after vitrectomy. At the last follow-up visit in 2019, the ultrawide field (UWF) color fundus photograph (I) shows the RCH regression.
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Figure 4. Patient P5. A, B, C, D, E: Color fundus photograph and FA of the right eye of patient P5. The color fundus photograph shows a well-
positioned scleral buckle and three peripheral retinal capillary hemangioblastoma (RCHs) (A, B, C) with scarring on the surrounding retina 
due to the cryotherapy (2 weeks after surgery, in 2010). On the right, the fluorescein angiography (FA) images highlight the blood supply of 
the three RCHs after cryotherapy and laser. A: Peripheral RCH located at 11 o’clock. B: Peripheral RCH at 8 o’clock. C: Peripheral RCH at 6 
o’clock. D: In 2019, ultrawide field (UWF) color fundus photography shows the effect of the scleral buckle and the peripheral three lesions at 
6, 8, and 11 o’clock. E: Color fundus photograph and FA of the right eye show a juxtapapillary fibrovascular membrane (white arrowheads).
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in some cases, such as RCHs localized adjacent to the optic 
disc or the macula, voluminous RCHs, and in cases of retinal 
detachment [8]. In the case of a large peripheral lesion, 
cryotherapy of the tumor is generally adopted as treatment. 
Nonetheless, there are no guidelines, or what additional, or 
alternative, therapeutic techniques should be used instead of 
laser photocoagulation for RCHs. Moreover, the definition of 
a successful treatment varies in literature. In a recent study, 
the American Academy of Ophthalmology defined as effec-
tive the treatment that determined normalization of the RCH 
feeder vessel diameters and an absence of RCH fluorescein 
leakage, detected using FA [8]. However, other parameters 
are described as valid, such as reduction of the tumor size. 
Observation and close follow-up can be effective manage-
ment in selected cases [15,16]; spontaneous regression of an 
RCH and life-long quiescent RCHs have been reported [17].
In this study, all the detected RCHs were treated using 
laser photocoagulation of the lesions. However, in four eyes 
(4/8; 50%) of four patients (4/6; 67%) additional treatments 
were required: cryotherapy and anti-VEGF IV injections. 
Specifically, three eyes (3/8; 38%) of three patients (3/6; 
50%) required retinal surgery due to the development of a 
retinal detachment. In the present series, a retinal detach-
ment was present at diagnosis in two eyes of two patients 
(P5 and P9), while it developed in OD of patient P9, who 
was lost at follow-up for 3 years. The patients all underwent 
episcleral surgery and concomitant transscleral cryotherapy. 
Patient P5 reached a final visual acuity of 20/20, and surgery 
was successful. However, chronic retinal detachment, NVG, 
and vision loss developed in two eyes of two patients (P9, 
P10). These two eyes also developed tiny new multiple retinal 
lesions, detectable using FA, showing progression of the 
ocular VHL disease.
The exudative and tractional effects of RCHs on the 
retina, and consequent retinal detachments, are the major 
causes of vision loss in patients with VHL syndrome [11]. 
Although pars plana vitrectomy has shown a good success 
rate for retinal detachment [18,19], there are few specific 
studies in literature on the results of episcleral surgery with a 
large number of patients with VHL syndrome.
No relapses or new lesions occurred in the remaining six 
eyes with RCHs, or in the contralateral eyes without RCHs 
(at diagnosis) during follow-up. In particular, among the 
four patients with unilateral RCHs at presentation, we did 
not detect the development of any further ophthalmic lesions 
during the mean follow-up of 99 months. Similarly, we did 
not observe any ocular involvements in the eyes of the 11 
patients with VHL syndrome with no RCHs at presentation 
during the mean follow-up of 101 months.
Different prevalence rates of new RCH development 
during follow-up in already treated eyes have been reported 
[7,11,13,15]. From the present results, it is therefore unlikely 
that patients with no ocular tumors at presentation progress 
to ophthalmic involvement in VHL syndrome within a period 
of approximately 8 years.
In fact, a second mutation of the VHL gene, or “second 
hit,” is necessary in the cells of the tissue that develop VHL-
related tumors: Only when a second mutation procedure in 
the somatic cells is added to the first mutation, which gener-
ally happens in the germinal cells, does the VHL protein 
lose its function, and the tumor develop [3]. Although the 
development of a VHL tumor in a new tissue may not neces-
sarily occur, or it can require a long time to develop, periodic 
follow-up is mandatory.
An uncommon manifestation of VHL ocular syndrome, 
distinct from an RCH lesion, consists of tiny new peripap-
illary vessels that may become a fibrotic proliferation or 
cause an epiretinal membrane (ERM) [20]. Their pathogenic 
mechanism may lie in the fact that the second mutation in 
the VHL gene affects a different cell precursor from the one 
that causes RCH to develop [20]. In the right eye of patient 
P5, a juxtapapillary fibrovascular membrane was detected at 
presentation. The fibrovascular complex was stable, without 
tractional effects on the retina or an increase in the vessel 
diameter size or number, during the 109 months of follow-up.
The presence of ERMs has been described in literature 
associated with VHL ocular involvement, in a few cases 
also leading to the formation of a macular hole [21,22]. This 
condition is attributable to the RCH therapy (laser or cryo-
therapy treatment) [21,22]; however, ERMs have also been 
described in eyes with still untreated RCHs [23]. It has been 
hypothesized that an ERM formation could be due to the 
biologic behavior of VHL syndrome; an electron-microscopic 
analysis of an excised ERM showed abnormal remodeling 
of collagenous stroma in VHL disease [22,23]. The ERM is 
usually removed surgically; however, a complete spontaneous 
separation of the membrane from the retinal surface, with 
normalization of the retinal profile, has been described as a 
rare event in VHL syndrome [22,23], and in one case, resolu-
tion of the ERM occurred after laser photocoagulation of the 
RCH [23].
In the present study, patient P2 presented with a macular 
pseudohole and a peripheral RCH at diagnosis. After 2 
months, and multiple laser sessions, the pseudohole evolved to 
an LMH and in less than 1 year, to a FTMH. It is interesting to 
notice the presence of tiny yellowish deposits in the macular 
hole bed, also visible at the OCT scan; they disappeared 
after vitrectomy which resulted in FTMH closure. Similar 
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deposits, also described as Klein’s tags [24], were observed 
in idiopathic holes, and their significance is uncertain [25]. 
However, they have been related to proliferations of RPE, 
caused by RPE exposure to the vitreous, or deposits of macro-
phages containing eosinophilic or lipofuscin material [25,26]. 
Their formation may be related to the inflammatory response 
following laser photocoagulation. Tiny yellowish deposits 
associated with FTMH have also been reported in six out of 
17 eyes that developed FTMH after momentary exposure to 
high-power handheld blue lasers [26]. These findings suggest 
that vitreous-related dynamics may be altered in the eyes that 
develop RCHs, and these modifications can easily lead to 
the formation of a vitreomacular interface disease. Not only 
could the VHL disease itself change the physiologic anatomy 
of the vitreous, but the RCH could also directly perform a 
tractional effect on the retina. Finally, the laser photocoagula-
tion treatment, and the following inflammation, may trigger 
further changes in an already altered vitreoretinal balance.
We report a new frameshift mutation in VHL in patient 
P1: c.461delC (p.Pro154Glnfs4*). This mutation is peculiar 
because the proline residue is normally highly conserved in 
individuals and families with VHL syndrome. Moreover, the 
residues from 63 to 154 form the seven-stranded β sandwich 
of the β domain, and in detail, p154 is the last codon located 
in the loop that connects the β to the α domain of the VHL 
protein [27]. Thus, this site could cause an important altera-
tion in the final conformation of the VHL protein [27]. In 
addition, the family segregation showed that this is also a de 
novo mutation. De novo mutations are described in fewer than 
one out of four patients with VHL syndrome [4,28]. However, 
studies conducted on the Chinese population suggested the 
possibility of a higher percentage, up to 56.3%, of sporadic 
mutations in the VHL gene [29]. In the present case series, 
three out of five patients where both parents were molecularly 
tested (P1, P8, and P10) carried a de novo mutation suggesting 
the possibility of a higher percentage than that described in 
literature. The mutation c.575C>T, (p.Pro192Leu) has been 
described in ClinVar; however, it is not reported in literature. 
We have described the clinical picture associated with this 
mutation.
Considering possible phenotype–genotype associations, 
different studies have searched for correlations between 
the mutation in VHL and the prevalence or the severity of 
ocular involvement, showing contradictory results [30]. It 
has been reported that complete protein deletions have the 
lowest prevalence of RCHs and the best prognosis in terms 
of visual outcome, when compared to other mutations in VHL 
[2]. In addition, truncating mutations (deletions, insertions, 
frameshift, and splice-site mutations) have shown a higher 
prevalence of ocular disease compared to missense muta-
tions [2,31]. Missense mutations, however, were related to a 
higher number of RCHs and complications [7,31]; a radical 
early treatment and more frequent follow-up, therefore, were 
indicated for patients carrying missense mutations [31]. In the 
present series, five out of six patients carrying a truncating 
mutation showed ocular involvement, and only one out of 
four patients carrying a missense mutation developed ocular 
lesions. A higher prevalence of the ophthalmic disease could 
be observed for truncating mutations in this series. However, 
severe disease (presence of multiple RCHs and eventual bilat-
eral disease) was present in four out of six patients: Three 
carried nonsense mutations and one a deletion. Therefore, 
these data differ from the results of previous studies, as 
nonsense mutations and deletion of the VHL protein were 
associated with bilateral and multiple RCHs or worse visual 
prognosis or both (P8, P5, P9, and P10) in the patients with 
VHL syndrome in the present study. It is likely that other 
unknown factors, other than the genotype, are responsible for 
the phenotype variability in ocular VHL disease.
In conclusion, patients with multiple RCHs, who devel-
oped RCH secondary effects, showed truncating mutations of 
the VHL protein. We recommend early screening and close 
monitoring, especially if RCHs are detected at presentation, 
for every patient with VHL syndrome, independently of the 
results of the molecular test for a missense or a truncating 
mutation in VHL. Furthermore, in the present patients we 
report that vitreoretinal interface abnormalities may be 
related to VHL disease and RCH therapy.
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